A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients

Trial Profile

A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs RG 7834 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2017 Status changed from recruiting to discontinued.
    • 01 Jun 2016 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
    • 01 Jun 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top